[go: up one dir, main page]

CA2257841A1 - Formulations aerosol medicinales au formoterol - Google Patents

Formulations aerosol medicinales au formoterol

Info

Publication number
CA2257841A1
CA2257841A1 CA002257841A CA2257841A CA2257841A1 CA 2257841 A1 CA2257841 A1 CA 2257841A1 CA 002257841 A CA002257841 A CA 002257841A CA 2257841 A CA2257841 A CA 2257841A CA 2257841 A1 CA2257841 A1 CA 2257841A1
Authority
CA
Canada
Prior art keywords
hfa
formoterol
aerosol formulations
medicinal aerosol
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002257841A
Other languages
English (en)
Other versions
CA2257841C (fr
Inventor
Martin J. Oliver
Simon G. Paling
Philip A. Jinks
Sukhbinder K. Jaiswal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2257841(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2257841A1 publication Critical patent/CA2257841A1/fr
Application granted granted Critical
Publication of CA2257841C publication Critical patent/CA2257841C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002257841A 1996-06-11 1997-06-02 Formulations aerosol medicinales au formoterol Expired - Lifetime CA2257841C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9612297.3 1996-06-11
GBGB9612297.3A GB9612297D0 (en) 1996-06-11 1996-06-11 Medicinal aerosol formulations
PCT/US1997/009471 WO1997047286A1 (fr) 1996-06-11 1997-06-02 Formulations aerosol medicinales au formoterol

Publications (2)

Publication Number Publication Date
CA2257841A1 true CA2257841A1 (fr) 1997-12-18
CA2257841C CA2257841C (fr) 2008-05-20

Family

ID=10795182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257841A Expired - Lifetime CA2257841C (fr) 1996-06-11 1997-06-02 Formulations aerosol medicinales au formoterol

Country Status (16)

Country Link
EP (2) EP0934057B1 (fr)
JP (1) JP5000793B2 (fr)
AR (1) AR009231A1 (fr)
AT (1) ATE275940T1 (fr)
AU (1) AU726382B2 (fr)
CA (1) CA2257841C (fr)
DE (1) DE69730723T2 (fr)
DK (1) DK0934057T3 (fr)
ES (1) ES2229366T3 (fr)
GB (1) GB9612297D0 (fr)
ID (1) ID19520A (fr)
NO (1) NO320403B1 (fr)
NZ (1) NZ333202A (fr)
PT (1) PT934057E (fr)
WO (1) WO1997047286A1 (fr)
ZA (1) ZA974546B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ID29605A (id) * 1998-10-17 2001-09-06 Boehringer Ingelheim Pharma Konsentrat bahan aktif dengan formoterol, yang sesuai untuk penyimpanan
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
DZ3358A1 (fr) 2000-05-22 2001-11-29 Chiesi Farma Spa Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TR200401980T4 (tr) 2001-07-02 2004-09-21 Chiesi Farmaceutici S.P.A. Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
ATE503687T1 (de) * 2002-08-27 2011-04-15 Schering Corp Verfahren zur herstellung von formulierungen für inhaliergeräte mit abgemessener dosis
CA2528479A1 (fr) 2003-06-13 2004-12-23 Altana Pharma Ag Combinaison de formoterol et de ciclesonide
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
SG147453A1 (en) * 2003-10-20 2008-11-28 Schering Corp Pharmaceutical aerosol compositions
EP1925293A3 (fr) * 2003-10-20 2010-01-13 Schering Corporation Compositions d'aérosol pharmaceutique
EP1595531A1 (fr) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
GB2443287B (en) * 2006-10-17 2009-05-27 Lipothera Inc Methods, compositions and formulations for the treatment of thyroid eye disease
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
WO2011038872A1 (fr) * 2009-10-02 2011-04-07 Chiesi Farmaceutici S.P.A. Formulations d'aérosol pharmaceutique de formotérol et de dipropionate de béclométasone
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2050905A1 (fr) * 1989-02-23 1990-08-24 George R. Felt Formules d'aerosol pour usage therapeutique
IE67185B1 (en) * 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ATE134509T1 (de) * 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
CA2111003A1 (fr) * 1991-06-10 1992-12-23 Julianne Fassberg Formulations d'aerosol sans chlorofluorocarbure
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
EP0717987B1 (fr) * 1991-12-18 2001-08-29 Minnesota Mining And Manufacturing Company Formulations d'aérosol en suspension
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
NZ333202A (en) 2000-06-23
JP2000513340A (ja) 2000-10-10
NO985720D0 (no) 1998-12-07
EP0934057A1 (fr) 1999-08-11
DK0934057T3 (da) 2005-01-24
NO320403B1 (no) 2005-11-28
ES2229366T3 (es) 2005-04-16
AU3373997A (en) 1998-01-07
ZA974546B (en) 1998-11-23
EP0934057B1 (fr) 2004-09-15
ATE275940T1 (de) 2004-10-15
AR009231A1 (es) 2000-04-12
AU726382B2 (en) 2000-11-02
JP5000793B2 (ja) 2012-08-15
EP1400239A1 (fr) 2004-03-24
DE69730723T2 (de) 2005-10-06
DE69730723D1 (de) 2004-10-21
CA2257841C (fr) 2008-05-20
GB9612297D0 (en) 1996-08-14
PT934057E (pt) 2004-12-31
ID19520A (id) 1998-07-16
NO985720L (no) 1999-02-11
WO1997047286A1 (fr) 1997-12-18

Similar Documents

Publication Publication Date Title
CA2257841A1 (fr) Formulations aerosol medicinales au formoterol
CA2258095A1 (fr) Compositions contenant de la tetrahydrolipstatine
AU732985B2 (en) Medicinal aerosol formulations comprising budesonide
CA2381329A1 (fr) Medicaments
CA2126244A1 (fr) Formulations d'aerosol en suspension
IL114596A (en) Pharmaceutical compositions containing an active substance blended with a carrier process for preparation thereof and their use for preparation of inhalated drugs
AU2003225915A1 (en) Formoterol and mometasone aerosol formulations
EP1277467A3 (fr) Formulations d' aérosols sans chlorofluorohydrocarbures
CA2087146A1 (fr) Compositions pharmaceutiques dont le mauvais gout est masque
CA2290521A1 (fr) Produits medicinaux pour aerosols
CA2125667A1 (fr) Medicaments aerosols avec propulseur fluorocarbone
CA2058428A1 (fr) Formulations analgesiques
CA2033725A1 (fr) Compositions pharmaceutiques et cosmetiques
CA2125665A1 (fr) Medicaments
EP0221041A3 (fr) Dérivés de benzimidazole, leur préparation et leur application comme médicaments
CA2311450A1 (fr) Compositions pharmaceutiques d'aerosols
AU6882796A (en) Pharmaceutical compositions and devices for their administration
AU7694896A (en) Prompt-release pharmaceutical compositions
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
EP0380880B1 (fr) Aérosols contenant le chromoglycate sodique
ATE154238T1 (de) Arzneimittel verzögerter wirkstoffabgabe
IE45282L (en) Pharmaceutical tablet formulation
EP0367509A3 (fr) Formulations
TH30777A (th) สารสูตรผสมของฟอร์โมทีรอลชนิดแอโรโซลที่ใช้รักษาโรค

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170602